Antibody drug conjugates are monoclonal antibodies that are attached with biologically active drugs. The combination of cytotoxic drugs and the targeting capacity of molecular antibodies allows antibody drug conjugates to perform targeted therapy to treat cancer patients. This allows a sensitive discrimination between cancerous tissues and healthy tissues. As the global antibody drug conjugates market is in an infancy stage, only three antibody drug conjugates have received market approval from the United States Food and Drug Administration (FDA).

Get Future Perspective of Antibody Drug Conjugates Industry at: http://bit.ly/2eALBv7

The first among the three, Mylotarg, was withdrawn from the global market by its manufacturer, Wyeth, Inc., a company of Pfizer, Inc., in June 2010. Mylotarg was primarily used for treating acute myelogenous leukemia. Thus, by drug, the global antibody drug conjugates market is now classified into Kadcyla and Adcertis.

Adcertis (Brentuximab vedotin) is a special antibody drug conjugate that is directed towards the CD30 protein and is expressed in systemic anaplastic large cell lymphoma and Hodgkin lymphoma. Seattle Genetics, in Feb 2011, submitted a Biologics License Application to the United States FDA for use in refractory Hodgkin lymphoma and relapsed anaplastic large cell lymphoma. The drug received accelerated approval from the United States FDA in August 2011. Adcertis led the global antibody drug conjugates market during the period between August 2011 and February 2013. In October 2012, Adcertis received marketing authorization from the European Medicines Agency.

Kadcyla (Trastuzumab emtansine) is an antibody drug conjugate that consists of the monoclonal antibody trastuzumab and is linked to cytotoxic agent mertansine DM1. In Italy, clinical trials on women suffering from HER2 positive breast cancer showed that Kadcyla improved their survival by 5.8 months. Due to this, Kadcyla received approval from the United States FDA in February 2013. Kadcyla, developed by Genentech, Inc., a subsidiary of F. Hoffmann-La Roche AG, is manufactured by Lonza group. The introduction of Kadcyla boosted the growth of the global antibody drug conjugates market during the period between 2012 and 2013.

By geography, the global antibody drug conjugates market is divided into Asia Pacific, North America, Europe, and Rest of the World. Most antibody drug conjugates in the development phase are for oncological indications and are propelled by the easy availability of monoclonal antibodies that target various types of cancer. At present, leading players in the global antibody drug conjugates market are targeting different domains other than oncology to develop antibody drug conjugates.

Read Current Market Structure of Antibody Drug Conjugates Market at: http://www.transparencymarketresearch.com/antibody-drug-conjugates-market.html

The high cost involved in the research and development activities to discover new antibody drugs is expected to restrict the growth of the global antibody drug conjugates market in the years to come. Biotest Pharmaceuticals Corporation, Synthon BV, Bayer AG, and Immunome